The challenging environment for health-care investing is not causing VCs to lose hope, but rather to get more resourceful and creative, said several investors at the Allicense biotechnology conference in San Francisco on Tuesday.
Bloomberg News
The IPO market remains sluggish at best, and even acquisitions don’t guarantee big, immediate returns, as milestone-structured deals in which acquirers pay less up front are becoming more common. The uncertainty brought about by health care reform and Food and Drug Administration policies add to the tough landscape.
In response, investors are employing a range of strategies, including spinning out “stranded assets” from big pharma companies, tailoring drug candidates specifically for acquisition, targeting rare diseases, going after orphan indications and targeting emerging markets.
To read the full, original article click on this link: Biotech VCs Figuring Out How To Roll With The Punches - Venture Capital Dispatch - WSJ
Author: Timothy Hay
